



Titre: Corrigendum: MRI-guided focal or integrated boost high dose rate
Title: brachytherapy for recurrent prostate cancer

Auteurs: Cynthia Ménard, Inmaculada Navarro-Domenech, Zhihu Liu (Amy),
Authors: Lisa Joseph, Maroie Barkati, Alejandro Berlín, Guila Delouya, Daniel
Taussky, Marie-Claude Beauchemin, Benedicte Nicolas, Samuel
Kadoury, Alexandra Rink, Srinivas Raman, Aravindhan
Sundaramurthy, Robert Weersink, Dominic Béliveau-Nadeau, Joelle
Helou, & Peter Chun

Date: 2022

Type: Article de revue / Article

Référence: Ménard, C., Navarro-Domenech, I., Liu, Z., Joseph, L., Barkati, M., Berlín, A.,
Citation: Delouya, G., Taussky, D., Beauchemin, M.-C., Nicolas, B., Kadoury, S., Rink, A.,
Raman, S., Sundaramurthy, A., Weersink, R., Béliveau-Nadeau, D., Helou, J., &
Chun, P. (2022). Corrigendum: MRI-guided focal or integrated boost high dose
rate brachytherapy for recurrent prostate cancer. *Frontiers in Oncology*, 12, 2
pages. <https://doi.org/10.3389/fonc.2022.1084708>

 **Document en libre accès dans PolyPublie**
Open Access document in PolyPublie

URL de PolyPublie: <https://publications.polymtl.ca/51916/>
PolyPublie URL:

Version: Erratum
Révisé par les pairs / Refereed

Conditions d'utilisation: Creative Commons Attribution 4.0 International (CC BY)
Terms of Use:


 **Document publié chez l'éditeur officiel**
Document issued by the official publisher

Titre de la revue: Frontiers in Oncology (vol. 12)
Journal Title:

Maison d'édition: Frontiers media sa
Publisher:

URL officiel: <https://doi.org/10.3389/fonc.2022.1084708>
Official URL:

Mention légale:
Legal notice:



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Cynthia Ménard
Cynthia.Menard@umontreal.ca

†These authors have contributed
equally to this work and share
first authorship

SPECIALTY SECTION
This article was submitted to
Genitourinary Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 30 October 2022
ACCEPTED 04 November 2022
PUBLISHED 17 November 2022

CITATION
Ménard C, Navarro-Domenech I,
Liu Z(A), Joseph L, Barkati M,
Berlin A, Delouya G, Taussky D,
Beauchemin M-C, Nicolas B,
Kadoury S, Rink A, Raman S,
Sundaramurthy A, Weersink R,
Beliveau-Nadeau D, Helou J and
Chung P (2022) Corrigendum:
MRI-guided focal or integrated
boost high dose rate brachytherapy
for recurrent prostate cancer.
Front. Oncol. 12:1084708.
doi: 10.3389/fonc.2022.1084708

COPYRIGHT
© 2022 Ménard, Navarro-Domenech,
Liu, Joseph, Barkati, Berlin, Delouya,
Taussky, Beauchemin, Nicolas, Kadoury,
Rink, Raman, Sundaramurthy, Weersink,
Beliveau-Nadeau, Helou and Chung.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer

Cynthia Ménard^{1*†}, Inmaculada Navarro-Domenech^{2†},
Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹,
Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹,
Marie-Claude Beauchemin¹, Benedicte Nicolas¹,
Samuel Kadoury³, Alexandra Rink², Srinivas Raman²,
Aravindhan Sundaramurthy², Robert Weersink²,
Dominic Beliveau-Nadeau¹, Joelle Helou² and Peter Chung²

¹Radiation Oncology, Centre Hospitaliser de l'Université de Montréal (CHUM), Montreal, QC, Canada, ²Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, ³Radiation Oncology, Polytechnique Montreal, Montreal, QC, Canada

KEYWORDS

prostate cancer, brachytherapy, salvage, radiotherapy, magnetic resonance imaging

A Corrigendum on

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer

By Ménard C, Navarro-Domenech I, Liu Z(A), Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin M-C, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J and Chung P (2022) *Front. Oncol.* 12:971344. doi: 10.3389/fonc.2022.971344

In the published article, there was an error in the author list. In the published manuscript the author list appears erroneously: Cynthia Ménard^{1*†}, Inmaculada Navarro-Domenech^{2†}, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung² on behalf of NIKE.

The corrected author list is as appears below.

Cynthia Ménard^{1*†}, Inmaculada Navarro-Domenech^{2†}, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude

Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhyan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung²

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.